Efficacy of favipiravir in COVID-19: A retrospective two center comparative study
Introduction: Favipiravir (FVP) is an antiviral, targeting RNA-dependent RNA polymerase. We aimed to evaluate the efficacy of FVP as a treatment for COVID-19. Methods: We conducted a retrospective study in two centers (San Martino University Hospital in Genova, Italy, and Marmara University Pendi...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2024-09-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/18039 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850193680377315328 |
|---|---|
| author | Elif Tukenmez Tigen Malgorzata Mikulska Buket Erturk Sengel Alessio Signori Silvia Dettori Stefania Tutino Abdullah Emre Guner Zekaver Odabasi Volkan Korten Matteo Bassetti |
| author_facet | Elif Tukenmez Tigen Malgorzata Mikulska Buket Erturk Sengel Alessio Signori Silvia Dettori Stefania Tutino Abdullah Emre Guner Zekaver Odabasi Volkan Korten Matteo Bassetti |
| author_sort | Elif Tukenmez Tigen |
| collection | DOAJ |
| description |
Introduction: Favipiravir (FVP) is an antiviral, targeting RNA-dependent RNA polymerase. We aimed to evaluate the efficacy of FVP as a treatment for COVID-19.
Methods: We conducted a retrospective study in two centers (San Martino University Hospital in Genova, Italy, and Marmara University Pendik Training and Research Hospital, Turkey). Adult patients (inpatients) diagnosed with COVID-19 between March and June 2020 were included. All patients in the Italian center received the standard of care (SoC) treatment, while in the Turkish center patients received FVP in addition to SoC.
Results: Six hundred-nineteen patients were analyzed (225 from Turkey, all treated with FVP, and 394 from Italy, none treated with FVP). Propensity score-matching was done in 142 patients (71 from the SoC group vs. 71 from the SoC + FVP group). A Higher requirement of NIV/CPAP (n = 38; 53.5%) was registered in the SoC group compared to the SoC + FVP group (n = 9; 12.7%). A higher frequency of intubation was registered in the SoC + FVP group (n = 25; 35.2% vs n = 13, 18.3%). There was a trend towards better survival in SoC + FVP treated patients with HR = 0.64 (95% CI 0.30-1.34). At 28 days the OS was, respectively, 70.3% (95% CI: 53.2-82.1) vs 80.3% (95% CI: 69.0-87.8).
Conclusions: The addition of FVP to SoC did not show a significant difference in survival and invasive and noninvasive (CPAP/NIMV) mechanical ventilation compared to standard of care in moderate and severe COVID-19-infected patients.
|
| format | Article |
| id | doaj-art-51803073e157429fb441a6e90b7fe7ec |
| institution | OA Journals |
| issn | 1972-2680 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-51803073e157429fb441a6e90b7fe7ec2025-08-20T02:14:11ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802024-09-01180910.3855/jidc.18039Efficacy of favipiravir in COVID-19: A retrospective two center comparative studyElif Tukenmez Tigen0Malgorzata Mikulska1Buket Erturk Sengel2Alessio Signori3Silvia Dettori4Stefania Tutino5Abdullah Emre Guner6Zekaver Odabasi7Volkan Korten8Matteo Bassetti9Marmara University Pendik Training and Research Hospital, Infectious Disease and Clinical Microbiology, Istanbul, TurkeyInfectious Diseases Unit, Ospedale Policlinico San Martino–IRCCS, Genova, ItalyMarmara University Pendik Training and Research Hospital, Infectious Disease and Clinical Microbiology, Istanbul, TurkeyUniversity of Genova, Department of Health Sciences- Section of Biostatistics, Genova, ItalyInfectious Diseases Unit, Ospedale Policlinico San Martino–IRCCS, Genova, ItalyInfectious Diseases Unit, Ospedale Policlinico San Martino–IRCCS, Genova, ItalyUniversity of Health Sciences, Public Health, İstanbul, TurkeyMarmara University Pendik Training and Research Hospital, Infectious Disease and Clinical Microbiology, Istanbul, TurkeyMarmara University Pendik Training and Research Hospital, Infectious Disease and Clinical Microbiology, Istanbul, TurkeyInfectious Diseases Unit, Ospedale Policlinico San Martino–IRCCS, Genova, Italy Introduction: Favipiravir (FVP) is an antiviral, targeting RNA-dependent RNA polymerase. We aimed to evaluate the efficacy of FVP as a treatment for COVID-19. Methods: We conducted a retrospective study in two centers (San Martino University Hospital in Genova, Italy, and Marmara University Pendik Training and Research Hospital, Turkey). Adult patients (inpatients) diagnosed with COVID-19 between March and June 2020 were included. All patients in the Italian center received the standard of care (SoC) treatment, while in the Turkish center patients received FVP in addition to SoC. Results: Six hundred-nineteen patients were analyzed (225 from Turkey, all treated with FVP, and 394 from Italy, none treated with FVP). Propensity score-matching was done in 142 patients (71 from the SoC group vs. 71 from the SoC + FVP group). A Higher requirement of NIV/CPAP (n = 38; 53.5%) was registered in the SoC group compared to the SoC + FVP group (n = 9; 12.7%). A higher frequency of intubation was registered in the SoC + FVP group (n = 25; 35.2% vs n = 13, 18.3%). There was a trend towards better survival in SoC + FVP treated patients with HR = 0.64 (95% CI 0.30-1.34). At 28 days the OS was, respectively, 70.3% (95% CI: 53.2-82.1) vs 80.3% (95% CI: 69.0-87.8). Conclusions: The addition of FVP to SoC did not show a significant difference in survival and invasive and noninvasive (CPAP/NIMV) mechanical ventilation compared to standard of care in moderate and severe COVID-19-infected patients. https://jidc.org/index.php/journal/article/view/18039FavipiravirefficacyCOVID-19antiviral |
| spellingShingle | Elif Tukenmez Tigen Malgorzata Mikulska Buket Erturk Sengel Alessio Signori Silvia Dettori Stefania Tutino Abdullah Emre Guner Zekaver Odabasi Volkan Korten Matteo Bassetti Efficacy of favipiravir in COVID-19: A retrospective two center comparative study Journal of Infection in Developing Countries Favipiravir efficacy COVID-19 antiviral |
| title | Efficacy of favipiravir in COVID-19: A retrospective two center comparative study |
| title_full | Efficacy of favipiravir in COVID-19: A retrospective two center comparative study |
| title_fullStr | Efficacy of favipiravir in COVID-19: A retrospective two center comparative study |
| title_full_unstemmed | Efficacy of favipiravir in COVID-19: A retrospective two center comparative study |
| title_short | Efficacy of favipiravir in COVID-19: A retrospective two center comparative study |
| title_sort | efficacy of favipiravir in covid 19 a retrospective two center comparative study |
| topic | Favipiravir efficacy COVID-19 antiviral |
| url | https://jidc.org/index.php/journal/article/view/18039 |
| work_keys_str_mv | AT eliftukenmeztigen efficacyoffavipiravirincovid19aretrospectivetwocentercomparativestudy AT malgorzatamikulska efficacyoffavipiravirincovid19aretrospectivetwocentercomparativestudy AT buketerturksengel efficacyoffavipiravirincovid19aretrospectivetwocentercomparativestudy AT alessiosignori efficacyoffavipiravirincovid19aretrospectivetwocentercomparativestudy AT silviadettori efficacyoffavipiravirincovid19aretrospectivetwocentercomparativestudy AT stefaniatutino efficacyoffavipiravirincovid19aretrospectivetwocentercomparativestudy AT abdullahemreguner efficacyoffavipiravirincovid19aretrospectivetwocentercomparativestudy AT zekaverodabasi efficacyoffavipiravirincovid19aretrospectivetwocentercomparativestudy AT volkankorten efficacyoffavipiravirincovid19aretrospectivetwocentercomparativestudy AT matteobassetti efficacyoffavipiravirincovid19aretrospectivetwocentercomparativestudy |